Suivre
AMPARO SÁNCHEZ NAVARRO
AMPARO SÁNCHEZ NAVARRO
Adresse e-mail validée de usal.es
Titre
Citée par
Citée par
Année
Paraquat exposure as an etiological factor of Parkinson's disease
RJ Dinis-Oliveira, F Remiao, H Carmo, JA Duarte, AS Navarro, ML Bastos, ...
Neurotoxicology 27 (6), 1110-1122, 2006
4162006
Full survival of paraquat-exposed rats after treatment with sodium salicylate
RJ Dinis-Oliveira, C Sousa, F Remiao, JA Duarte, AS Navarro, ML Bastos, ...
Free Radical Biology and Medicine 42 (7), 1017-1028, 2007
1522007
P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity
RJ Dinis-Oliveira, F Remiao, JA Duarte, R Ferreira, AS Navarro, ...
Free Radical Biology and Medicine 41 (8), 1213-1224, 2006
1462006
Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients
N Revilla, MV Calvo, A Domínguez-Gil, A Sánchez Navarro
Intensive care medicine 33 (2), 279-285, 2007
1242007
Sodium salicylate prevents paraquat-induced apoptosis in the rat lung
RJ Dinis-Oliveira, C Sousa, F Remiao, JA Duarte, R Ferreira, AS Navarro, ...
Free Radical Biology and Medicine 43 (1), 48-61, 2007
892007
Development and validation of an HPLC method for vancomycin and its application to a pharmacokinetic study
MJ de Jesús Valle, FG López, AS Navarro
Journal of pharmaceutical and biomedical analysis 48 (3), 835-839, 2008
882008
A physico-chemical study of the interaction of ciprofloxacin and ofloxacin with polivaient cations
BM Sánchez, MM Cabarga, AS Navarro, ADG Hurlé
International journal of pharmaceutics 106 (3), 229-235, 1994
651994
New formulations of amoxicillin/clavulanic acid
AS Navarro
Clinical pharmacokinetics 44 (11), 1097-1115, 2005
502005
Grupo de Trabajo Atención Farmacéutica. Sociedad Española de Farmacia Hospitalaria. Bases de la atención farmacéutica en Farmacia Hospitalaria
MV Calvo, M Alós, J Giraldez, MV Inar Calvo, M Alós, J Giráldez, ...
Farm Hosp 30, 120-123, 2006
452006
Neuronal and mixed neuronal glial tumors associated to epilepsy. A heterogeneous and related group of tumours
S Ramón, A Moreno, J de Felipe, RG Sola, A Navarro
Histology and histopathology 16 (2), 613-622, 2001
402001
Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions
A Domínguez‐Gil Hurlé, A Sánchez Navarro, MJ Garcia Sanchez
Clinical microbiology and infection 12, 97-106, 2006
382006
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis
MMF de Gatta, DS Buelga, AS Navarro, A Dominguez-Gil, MJ García
Clinical pharmacokinetics 48 (4), 273-280, 2009
332009
Pulmonary versus systemic delivery of antibiotics: Comparison of vancomycin dispositions in the isolated rat lung
MJ de Jesús Valle, FG López, ADG Hurlé, AS Navarro
Antimicrobial agents and chemotherapy 51 (10), 3771-3774, 2007
302007
Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function
F Álvarez-Lerma, A Allepuz-Palau, MP Gracia, M Ágeles León, A Navarro, ...
Journal of chemotherapy 20 (1), 93-100, 2008
292008
Comparative study of the influence of Ca2+ on absorption parameters of ciprofloxacin and ofloxacin
AS Navarro, MM Cabarga, ADG Hurlé
Journal of Antimicrobial Chemotherapy 34 (1), 119-125, 1994
281994
Effects of two cations on gastrointestinal absorption of ofloxacin
M Martinez Cabarga, A Sanchez Navarro, CI Colino Gandarillas, ...
Antimicrobial agents and chemotherapy 35 (10), 2102-2105, 1991
281991
Oral absorption of ofloxacin administered together with aluminum
A Sanchez Navarro, M Martinez Cabarga, A Dominguez-Gil Hurle
Antimicrobial agents and chemotherapy 38 (10), 2510-2512, 1994
261994
Toxicological evaluation of lactose and chitosan delivered by inhalation
MJ de Jesús Valle, RJ Dinis-Oliveira, F Carvalho, ML Bastos, AS Navarro
Journal of Biomaterials Science, Polymer Edition 19 (3), 387-397, 2008
252008
The effect of liposome-entrapped desferrioxamine on Leishmania donovani in vitro
M Segovia, A Navarro, JM Artero
Annals of Tropical Medicine & Parasitology 83 (4), 357-360, 1989
251989
Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections
MD Sánchez Navarro, ML Sayalero Marinero, A Sánchez Navarro
Journal of Antimicrobial Chemotherapy 50 (1), 67-72, 2002
242002
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20